{"id":"nct:NCT07610278","kind":"trial","title":"A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2026,"published":"2026-05-27","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07610278","source_url":"https://clinicaltrials.gov/study/NCT07610278","archive_url":"https://space-kitty.com/papers/nct:NCT07610278","updated":"2026-07-30","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Hypercholesterolaemia"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"sponsor":"Novartis Pharmaceuticals","conditions":["Hypercholesterolaemia"],"interventions":["DRUG: QCZ484","DRUG: Inclisiran","DRUG: QCZ484 placebo","DRUG: Inclisiran placebo"],"start_date":"2026-05-29","start_date_type":"ACTUAL","primary_completion_date":"2027-04-28","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}